Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992472 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Prochlorperazine Suppositories, 25 mg
A Phase 1 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00992472 is a Phase 1 study that has completed, run by Padagis. The registered enrollment target is 42 participants.
The verdict
NCT00992472, a Phase 1 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.
Interventions
- DRUG Prochlorperazine suppositories, 25mg
- DRUG Compazine® suppositories, 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992472
The ClinicalTrials.gov registry entry for NCT00992472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prochlorperazine suppositories, 25mg is the first listed.
NCT00992472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992472 about?
NCT00992472 is a clinical study titled "Bioavailability of Prochlorperazine Suppositories, 25 mg". The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.
What is the current status of trial NCT00992472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants.
What interventions are being tested in trial NCT00992472?
The interventions under investigation include: Prochlorperazine suppositories, 25mg (DRUG), Compazine® suppositories, 25mg (DRUG).
Who is sponsoring clinical trial NCT00992472?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.